ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

PHASE3CompletedINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2011

Conditions
Severe Sepsis
Interventions
DRUG

eritoran tetrasodium

Intravenous infusion at a total dose of 105 mg.

DRUG

Placebo

Matching placebo; intravenous infusion.

Trial Locations (251)

Unknown

Birmingham

Mobile

Mesa

Loma Linda

Marysville

Orange

San Diego

Santa Barbara

Denver

New Haven

Newark

Washington D.C.

Atlantis

Clearwater

Gainesville

Miami

Orlando

Pensacola

Atlanta

Decatur

Idaho Falls

Chicago

Oak Park

Peoria

Indianapolis

Des Moines

Iowa City

Kansas City

Topeka

Lexington

Louisville

Opelousas

Shreveport

Baltimore

Boston

Springfield

Detroit

Pontiac

Kansas City

St Louis

Butte

Omaha

Englewood

Hackensack

Buffalo

Mineola

New Hyde Park

New York

Rochester

Durham

Greenville

Cleveland

Columbus

Toledo

Danville

Hershey

Philadelphia

Pittsburgh

Providence

Columbia

Memphis

Nashville

Fort Worth

Houston

Lubbock

Charlottesville

Norfolk

Roanoke

Tacoma

Buenos Aires

Córdoba

Santa Fe

New South Wales

St Leonards

Westmead

Queensland

Southport

Adelaide

Woodville

Heidelberg

Melbourne

Parkville

Nedlands

Perth

Box Hill

Salzburg

Vienna

Braine-l'Alleud

Brussels

Ghent

Liège

Mons

Ottignies

Seraing

Yvoir

Belo Horizonte

Curitba

Fontaleza

Joinville

Porto Alegre

Rio de Janeiro

São Paulo

Calgary

Edmonton

Vancouver

Victoria

Winnipeg

Saint John

Halifax

Toronto

Windsor

Greenfield Park

Montreal

Québec

Santiago

Temuco

Valdivia

Viña del Mar

Brno

Havlíčkův Brod

Hradec Králové

Plyzen

Prague

Amiens

Besançon

Colombes

Corbeil-Essonnes

Evry Courcouronnes

La Roche-sur-Yon

La Tronche

Le Chesnay

Limoges

Montauban

Nîmes

Paris

Saint-Michel

Tours

Aachen

Berlin

Bonn

Cologne

Erfurt

Erlangen

Frankfurt

Geißen

Hanover

Jena

Krefeld

Ludwigshafen

München

Hong Kong

Afula

Hadera

Haifa

Holon

Jerusalem

Kfar Saba

Nahariya

Petah Tikva

Tel Litwinsky

Ẕerifin

Bari

Busto Arsizio

Cesana Torinese

Milan

Monza

Novara

Pavia

Trieste

Verona

Aichi

Bunkyō City

Chūō

Fukuoka

Fukushima

Hachiōji

Hamamatsu

Hirosaki

Hiroshima

Iizuka

Kagoshima

Kamagaya

Kanagawa

Kishiwada

Kobe

Kochi

Kumamoto

Kyoto

Morioka

Osaka

Saga

Sapporo

Sendai

Shinagawa City

Suita

tabashi City

Ube

Utsunomiya

Yonago

Yotsukaidou

Amsterdam

Apeldoorn

Ede

Groningen

Leeuwarden

Rotterdam

s'Hertogenbosch

Tilburg

Utrecht

Zwolle

Bielsko-Biala

Groszisk Mazowiecki

Krakow

Lodz

Poznan

Warsaw

Almada

Amadora

Lisbon

Alberton

Cape Town

Centurion

Johannesburg

Kimberley

Parow

Pietermaritzburg

Roodepoort

Seoul

Alcala de Henares Madrid

Barcelona

Burgos

Cataluna

Getafe

Madrid

Sabadell

Santiago de Compostela

Tarragona

Bern

Geneva

Lausanne

Taichung

Taipei

Taoyuan District

Yung Kang City

Birmingham

Leeds

Livingston

London

Nottingham

Plymouth

Southampton

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00334828 - ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis | Biotech Hunter | Biotech Hunter